A
Adnexus
Engages in the development of Adnectins biologics and medicines in the United States
About Adnexus
Adnexus Therapeutics, acquired by Bristol-Myers Squibb, is a biotechnology company focused on developing Adnectins, a proprietary class of targeted biologics.
Read full description
These therapeutic proteins are engineered from the scaffold of human fibronectin, designed to bind to a wide range of biological targets with high affinity and specificity, similar to monoclonal antibodies but with the potential for a smaller size and more stable structure. The company's business model centered on leveraging its platform to discover and develop novel drug candidates for various therapeutic areas, particularly oncology.
By creating a pipeline of potential first-in-class protein therapeutics, Adnexus aimed to address unmet medical needs. The acquisition by Bristol-Myers Squibb integrated Adnexus's discovery platform and preclinical programs into a major pharmaceutical company's research and development engine, providing the resources to advance these novel protein therapeutics through clinical trials and towards commercialization. This strategic move highlights a common business model in the biotech industry, where smaller, specialized firms develop innovative technologies that are then acquired by larger companies for further development and market access.
At a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- Waltham, United States
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 88.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Adnexus.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2007 | $16M | $62M | Venrock · Atlas Venture · Polaris Partners · Flagship Pioneering | — |
| SERIES BOther financing | Jun 2006 | $27M | $108M | Atlas Venture · Polaris Partners · Flagship Pioneering · Venrock | — |
Growth signals
Latest recorded traffic for Adnexus is 230 monthly website visits, up 0% over the last three months. Adnexus's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Series B and later1 investor entered at this stage
HBM Healthcare Investments
Other known investors1 additional known investor
Massachusetts General Hospital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adnexus on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adnexus’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.